Avid Bioservices and Bioreliance Team Up To Provide Eukaryotic Cell Banking Services to the Biopharmaceutical Industry

Peregrine Pharmaceuticals Announces First Quarter 2006 Financial Results

Peregrine Pharmaceuticals and New Approaches to Brain Tumor Therapy (NABTT) Consortium Initiate Cotara(R) Brain Cancer Trial

Peregrine Pharmaceuticals Enters Into Licensing Agreement With Medarex to Develop Vascular Targeting Agents

Peregrine Pharmaceuticals Initiates Tarvacin(TM) Phase I Hepatitis C Virus Trial

Peregrine Pharmaceuticals and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Sign Agreement for Anti-Viral Testing

Peregrine Pharmaceuticals Announces Fiscal Year 2005 Financial Results and Operational Highlights

Peregrine Pharmaceuticals Announces $6.7 Million Investment From One Institutional Investor

Peregrine Pharmaceuticals Presents Data Supporting Broad Spectrum Anti-Viral Potential of Tarvacin(TM) at BIO 2005

Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial